Intravitreal anti-vascular endothelial growth factor for the treatment of chronic central serous retinopathy: a meta-analysis of the literature
Objective The purpose of this study was to evaluate the role of anti-vascular endothelial growth factor (anti-VEGF) treatment on the functional and structural parameters of chronic central serous retinopathy (CSR).Methods PubMed was used to systematically review literature published from 1 January 2...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-12-01
|
| Series: | BMJ Open Ophthalmology |
| Online Access: | https://bmjophth.bmj.com/content/8/1/e001310.full |
| _version_ | 1797367529997336576 |
|---|---|
| author | Monique Munro Mathew Palakkamanil Abhishek Sethi Feisal Adatia |
| author_facet | Monique Munro Mathew Palakkamanil Abhishek Sethi Feisal Adatia |
| author_sort | Monique Munro |
| collection | DOAJ |
| description | Objective The purpose of this study was to evaluate the role of anti-vascular endothelial growth factor (anti-VEGF) treatment on the functional and structural parameters of chronic central serous retinopathy (CSR).Methods PubMed was used to systematically review literature published from 1 January 2009 to 1 July 2022. Studies were included if patients in their cohort had symptoms for more than 3 months, anti-VEGF treatment was provided and the following outcomes were reported: best-corrected visual acuity (BCVA), central macular thickness (CMT) and proportion of subretinal fluid (SRF) resolution.Results 339 eyes met inclusion criteria with a mean patient age of 45.8±4.9 years. The weighted mean baseline BCVA for the 20 studies was 0.39±0.23 logMAR, which improved to 0.28±0.24 after treatment with anti-VEGF injections (p=0.069). The weighted baseline CMT for the 20 studies decreased from 395.2±52.0 µm to 243.0±41.9 µm (p<0.001). The weighted overall percentage of SRF resolution was 68.4%.Conclusion Anti-VEGF treatment demonstrated significantly decreased macular thickness and resolution of SRF in the treatment of chronic CSR without any reported adverse effects. However, BCVA did not significantly improve with pharmacotherapy. |
| first_indexed | 2024-03-08T17:19:39Z |
| format | Article |
| id | doaj.art-33b43aa93f304b8b94550b62fd6d8ac8 |
| institution | Directory Open Access Journal |
| issn | 2397-3269 |
| language | English |
| last_indexed | 2024-03-08T17:19:39Z |
| publishDate | 2023-12-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open Ophthalmology |
| spelling | doaj.art-33b43aa93f304b8b94550b62fd6d8ac82024-01-03T07:55:07ZengBMJ Publishing GroupBMJ Open Ophthalmology2397-32692023-12-018110.1136/bmjophth-2023-001310Intravitreal anti-vascular endothelial growth factor for the treatment of chronic central serous retinopathy: a meta-analysis of the literatureMonique Munro0Mathew Palakkamanil1Abhishek Sethi2Feisal Adatia3Divsion of Ophthalmology, Department of Surgery, University of Calgary, Calgary, Alberta, CanadaDepartment of Ophthalmology and Visual Sciences, University of Alberta, Edmonton, Alberta, CanadaIllinois Eye and Ear Infirmary, University of Illinois Chicago, Chicago, Illinois, USADivsion of Ophthalmology, Department of Surgery, University of Calgary, Calgary, Alberta, CanadaObjective The purpose of this study was to evaluate the role of anti-vascular endothelial growth factor (anti-VEGF) treatment on the functional and structural parameters of chronic central serous retinopathy (CSR).Methods PubMed was used to systematically review literature published from 1 January 2009 to 1 July 2022. Studies were included if patients in their cohort had symptoms for more than 3 months, anti-VEGF treatment was provided and the following outcomes were reported: best-corrected visual acuity (BCVA), central macular thickness (CMT) and proportion of subretinal fluid (SRF) resolution.Results 339 eyes met inclusion criteria with a mean patient age of 45.8±4.9 years. The weighted mean baseline BCVA for the 20 studies was 0.39±0.23 logMAR, which improved to 0.28±0.24 after treatment with anti-VEGF injections (p=0.069). The weighted baseline CMT for the 20 studies decreased from 395.2±52.0 µm to 243.0±41.9 µm (p<0.001). The weighted overall percentage of SRF resolution was 68.4%.Conclusion Anti-VEGF treatment demonstrated significantly decreased macular thickness and resolution of SRF in the treatment of chronic CSR without any reported adverse effects. However, BCVA did not significantly improve with pharmacotherapy.https://bmjophth.bmj.com/content/8/1/e001310.full |
| spellingShingle | Monique Munro Mathew Palakkamanil Abhishek Sethi Feisal Adatia Intravitreal anti-vascular endothelial growth factor for the treatment of chronic central serous retinopathy: a meta-analysis of the literature BMJ Open Ophthalmology |
| title | Intravitreal anti-vascular endothelial growth factor for the treatment of chronic central serous retinopathy: a meta-analysis of the literature |
| title_full | Intravitreal anti-vascular endothelial growth factor for the treatment of chronic central serous retinopathy: a meta-analysis of the literature |
| title_fullStr | Intravitreal anti-vascular endothelial growth factor for the treatment of chronic central serous retinopathy: a meta-analysis of the literature |
| title_full_unstemmed | Intravitreal anti-vascular endothelial growth factor for the treatment of chronic central serous retinopathy: a meta-analysis of the literature |
| title_short | Intravitreal anti-vascular endothelial growth factor for the treatment of chronic central serous retinopathy: a meta-analysis of the literature |
| title_sort | intravitreal anti vascular endothelial growth factor for the treatment of chronic central serous retinopathy a meta analysis of the literature |
| url | https://bmjophth.bmj.com/content/8/1/e001310.full |
| work_keys_str_mv | AT moniquemunro intravitrealantivascularendothelialgrowthfactorforthetreatmentofchroniccentralserousretinopathyametaanalysisoftheliterature AT mathewpalakkamanil intravitrealantivascularendothelialgrowthfactorforthetreatmentofchroniccentralserousretinopathyametaanalysisoftheliterature AT abhisheksethi intravitrealantivascularendothelialgrowthfactorforthetreatmentofchroniccentralserousretinopathyametaanalysisoftheliterature AT feisaladatia intravitrealantivascularendothelialgrowthfactorforthetreatmentofchroniccentralserousretinopathyametaanalysisoftheliterature |